- Liz Highleyman | 23 May 2016
HIV-positive people with hepatitis B virus (HBV)
co-infection had impaired CD4 cell recovery after starting antiretroviral therapy (ART)
and a higher risk of death than those without hepatitis B, but use of ...
- Roger Pebody | 22 April 2016
People who miss appointments for HIV care are more likely to
have money problems, childcare responsibilities and a history of depression
according to a recent UK study. While poor attendance was more common ...
- Liz Highleyman | 12 April 2016
Direct-acting antiviral therapy for hepatitis C
delivered by non-specialists such as primary care physicians and nurse
practitioners is safe and effective – even for the most difficult-to-treat
patients – and could potentially help ...
- Liz Highleyman | 08 April 2016
VRC01, a broadly neutralising antibody
targeting HIV's CD4 binding site, was able to modestly delay the return of
viral replication following interruption of antiretroviral therapy (ART), according
to a study presented at the ...
- Liz Highleyman | 07 April 2016
A growing proportion of people
with HIV are reaching an undetectable viral load on antiretroviral therapy
(ART), according to a pair of studies from the US Centers for Disease Control
and Prevention presented ...
- Michael Carter | 01 April 2016
An investigational
antiretroviral agent that maintains drug levels that are able to inhibit HIV up
to six months after dosing could represent a “paradigm shift” in HIV therapy
and prophylaxis, according to research ...
- Liz Highleyman | 31 March 2016
The SSRI antidepressant
paroxetine (Paxil) was associated
with modest improvement in cognitive function and reduced central nervous
system inflammation in people with HIV-related neurocognitive disorder, but the
antifungal drug fluconazole showed no apparent benefit ...
- Liz Highleyman | 24 March 2016
Providing culturally tailored support programmes for
black men who have sex with men can increase their likelihood of maintaining
adherence to pre-exposure prophylaxis (PrEP) for HIV prevention, helping to address
a key public ...
- Liz Highleyman | 18 March 2016
A long-acting bio-engineered molecule
with a triple mechanism of action demonstrated potent antiviral activity and worked
against HIV that developed resistance to any one of the three mechanisms in a
laboratory study, and ...
- Liz Highleyman | 16 March 2016
Participants taking tenofovir/emtricitabine
(Truvada) for pre-exposure
prophylaxis (PrEP) continued to have high rates of sexually transmitted
infections (STIs) in two US PrEP demonstration projects, according to a pair of
reports at the Conference on ...
- Theo Smart | 15 March 2016
HIV-related risk factors seem to increase the risk of
stroke – the sudden death of brain cells due to a rupture or obstruction of
blood vessels in the brain – according to ...
- Liz Highleyman | 14 March 2016
Sofosbuvir/velpatasvir, a forthcoming combination that
effectively treats all hepatitis C virus (HCV) genotypes, can be safely used
with most boosted antiretrovirals for people with HIV and HCV co-infection,
according to a study presented ...
- Liz Highleyman | 11 March 2016
Transgender women have among the highest
rates of HIV infection but little is known about HIV prevalence among trans
men, Tonia Poteat of Johns Hopkins Bloomberg School of Public Health said in ...
- Roger Pebody | 10 March 2016
Large internet surveys of American gay men show that the
proportion who have heard of pre-exposure prophylaxis (PrEP) jumped from 45% in
2012 to 68% in 2015, with around half of men ...
- Liz Highleyman | 09 March 2016
Extensive epidemiological investigation followed by
prevention and treatment interventions have largely succeeded in controlling an
outbreak of HIV and hepatitis C virus (HCV) infection in rural Indiana, USA,
linked to injection of prescription ...
- Liz Highleyman | 08 March 2016
Sofosbuvir plus the investigational HCV NS5A inhibitor ravidasvir, with or without ribavirin, cured 95 to 100% of people with hepatitis C
virus (HCV) genotype 4, the most common type in Egypt, ...
- Roger Pebody | 07 March 2016
Rather than treatment side-effects having a negative impact
on people’s quality of life when they start HIV treatment, data from the large
randomised START study show a modest but statistically significant improvement
in ...
- Theo Smart | 04 March 2016
A study in KwaZulu-Natal,
South Africa, evaluating the social networks as well as clinical and genotypic
data from individuals with extensively drug resistant tuberculosis (XDR-TB)
has concluded that transmission – in
both hospitals and ...
- Gus Cairns | 03 March 2016
Two studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) outlined the
first findings from the NEXT-PrEP study, otherwise known as HPTN 069. As
its name indicates, it explores ...
- Liz Highleyman | 02 March 2016
Increasing diagnosis, care and treatment of people living
with HIV could lead to a large decrease in HIV incidence, preventing some
168,000 new infections by the year 2020, according to a new ...
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...